Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach

International Journal of Oncology

Volumn 29, Issue 6, 2006, Pages 1371-1379

  Pernasetti, Flavia ^a,c   Nickel, Jeffrey ^a   Clark, Derek ^a   Baeuerle, Patrick A ^a,b   Van Epps, Dennis ^a   Freimark, Bruce ^a  

^a Micromet Corporation   (United States)

^b MICROMET AG   (Germany)

^c NONE   (United States)

Author keywords

Antiangiogenic therapy; Denatured collagen; Extracellular matrix; Monoclonal antibody

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CD31 ANTIGEN; COLLAGEN TYPE 4; EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; PACLITAXEL;

ADULT; AGED; ANIMAL; ARTICLE; BASEMENT MEMBRANE; BREAST TUMOR; CELL GROWTH; CHICK EMBRYO; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; EXTRACELLULAR MATRIX; FEMALE; HUMAN; IMMUNOLOGY; MALE; MELANOMA; METABOLISM; MIDDLE AGED; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASEMENT MEMBRANE; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CHICK EMBRYO; COLLAGEN TYPE IV; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG SYNERGISM; EPITOPES; EXTRACELLULAR MATRIX; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MELANOMA; MICE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL;

EID: 34249337241     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.6.1371     Document Type: Article

References (29)

1. Akalu A and Brooks P: Matrix, extracellular and interstitial. In: Encyclopedia of Molecular Cell Biology and Molecular Medicine. 2nd edition. Meyers RA (ed). Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp45-70, 2005.
2. Paku S and Paweletz N: First steps of tumor-related angiogenesis. Lab Invest 65: 334-346, 1991.
3. Gagne P, Akalu A and Brooks PC: Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment. Expert Rev Anticancer Ther 4: 129-140, 2004. (Pubitemid 38208492)
4. Moses MA, Klagsbrun M and Shing Y: The role of growth factors in vascular cell development and differentiation. Int Rev Cytol 97: 153-165, 1995.
5. Cornelius LA, Nehring LC, Roby JD, Parks WC and Welgus HG: Human dermal microvascular endothelial cells produce matrix metalloproteases in response to angiogenic factors and migration. J Invest Dermatol 105: 170-176, 1995.
6. Ingber DE, Madri JA and Folkman J: Endothelial growth factors and extracellular matrix regulate DNA synthesis through modulation of cell and nuclear expansion. In Vitro Cell Dev Biol 23: 387-394, 1987.
7. Brown JC and Timpl R: The collagen superfamily. Int Arch Allergy Immunol 107: 484-490, 1995.
8. Kalluri R: Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3: 422-433, 2003.
9. Chang C and Werb Z: The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 11: 537-543, 2001.
10. Xu J, Rodriguez D, Petitclerc E, et al: Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 154: 1069-1079, 2001.
11. Xu J, Rodriguez D, Kim JJ and Brooks PC: Generation of monoclonal antibodies to cryptic collagen sites by using subtractive immunization. Hybridoma 19: 375-385, 2000.
12. Brooks PC, Montgomery AM and Cheresh DA: Use of the 10-day old chicken embryo model for studying angiogenesis. Methods Mol Biol 129: 257-269, 1999.
13. Hoshida T, Sanamura M, Duda DG, et al: Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor. Pancreas 2: 111-121, 2002.
14. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996. (Pubitemid 26272076)
15. Folkman J: Tumor angiogenesis: therapeutic implication. N Engl J Med 285: 1182-1186, 1971.
16. The kidney. In:. Robbins Pathologic Basis of Disease. 4th edition. Cotran RS, Kumar V and Robbins SL (eds). W.B. Saunders Company, Philadelphia, PA, pp1011-1082, 1989.
17. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of taxol, an active drug in the treatment of breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991.
18. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
19. Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D and Gasparinni G: Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 5: 237-256, 2002.
20. Ferrara N: VEGF as a therapeutic target in cancer. Oncology 69: 11-16, 2005.
21. O'Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994. (Pubitemid 24324921)
22. Brooks PC: Role of integrins in angiogenesis. Eur J Cancer 32A: 2423-2429, 1996.
23. Seandel M, Noack-Kunnmann K, Zhu D, Aimes RT and Quigley JP: Growth factor-induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen. Blood 97: 2323-2332, 2001.
24. Senger DR and Perruzzi CA: Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochim Biophys Acta 1314: 13-24, 1996.
25. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG and Quaranta V: Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 277: 225-228, 1997. (Pubitemid 27446075)
26. O'Reilly MS: Therapeutic strategies using inhibitors of angiogenesis. In: Methods and Molecular Biology. Vol. 223. El Deiry WS (ed). Humana Press, Totowa, NJ, pp599-633, 2003.
27. Teicher BA: A systems approach to cancer therapy. (Antioncogenics + Standard cytotoxics > mechanism(s) of interaction). Cancer Metastasis Rev 5: 247-272, 1996.
28. Yardley DA: Gemcitabine plus paclitaxel in breast cancer. Semin Oncol 32 (suppl. 6): S14-S21, 2005.
29. Horwitz SB: Mechanisms of action of taxol. Trends Pharmacol Sci 13: 134-136, 1992.